Contact this trialFirst, we need to learn more about you.
Monoterpene
Perillyl Alcohol for Glioblastoma
Recruiting1 awardPhase 1 & 2
Seattle, Washington
This trial is testing a new way to administer a drug, perillyl alcohol, to patients with brain tumors. The goal is to see if it is safe and effective. Up to 24 patients will be enrolled in the first phase of the trial, and 25 in the second phase. The drug will be administered four times a day for 28 days, and patients will be monitored for side effects and effectiveness.
Fill-in a few details and create your profileHaving a profile will help us send you recommended trials and speed up your application in the future.
We will keep your details privateWe won’t share unless you give us permission. By completing this form you agree to our privacy policy
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.